XML 78 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
Revenue Recognition - Schedule of net revenue from collaboration arrangement (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue Recognition and Collaborative Arrangements      
Total royalty revenue $ 358,711 $ 310,463 $ 331,339
Royalty revenue      
Revenue Recognition and Collaborative Arrangements      
Less: amortization of capitalized fees paid (13,800) (13,800) (13,800)
Total royalty revenue 241,733 238,846 311,645
GSK      
Revenue Recognition and Collaborative Arrangements      
Total royalty revenue 241,733 238,846 311,645
GSK | Royalty revenue      
Revenue Recognition and Collaborative Arrangements      
Total royalties 255,556 252,669 325,468
Less: amortization of capitalized fees paid (13,823) (13,823) (13,823)
GSK | RELVAR/BREO      
Revenue Recognition and Collaborative Arrangements      
Total royalties 207,925 208,042 215,034
GSK | ANORO      
Revenue Recognition and Collaborative Arrangements      
Total royalties 47,631 44,627 38,405
GSK | TRELEGY      
Revenue Recognition and Collaborative Arrangements      
Total royalties $ 0 $ 0 $ 72,029